A bioactive sphingolipid; inhibits IL-4 production by 23.24% in EL4 T cells (10 μM); stimulates NF-κB activity in C6 glioma cells and activates mast cells in a concentration-dependent manner; cytotoxic to U937 cells in vitro (IC50 = 33 μM); suppresses the allogeneic MLR response in murine spleen cells

C2 Galactosylceramide (d18:1/2:0) – 10 mg

Brand:
Cayman
CAS:
35823-61-1
Storage:
-20
UN-No:
Non-Hazardous - /

C2 Galactosylceramide is a bioactive sphingolipid.{13011,38647,39566} It inhibits IL-4 production by 23.24% in EL4 T cells when used at a concentration of 10 μM.{13011} C2 Galactosylceramide stimulates NF-κB activity in C6 glioma cells and activates mast cells in a concentration-dependent manner. It is cytotoxic to U937 cells in vitro (IC50 = 33 μM). C2 Galactosylceramide also suppresses the allogeneic mixed leukocyte reaction (MLR) response in murine spleen cells in a concentration-dependent manner.{39566} [Matreya, LLC. Catalog No. 1325]  

 

Available on backorder

Add to quotes
SKU: 24465 - 10 mg Category:

Description

A bioactive sphingolipid; inhibits IL-4 production by 23.24% in EL4 T cells (10 μM); stimulates NF-κB activity in C6 glioma cells and activates mast cells in a concentration-dependent manner; cytotoxic to U937 cells in vitro (IC50 = 33 μM); suppresses the allogeneic MLR response in murine spleen cells,

Formal name: N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-acetamide

Synonyms:  Galactosylceramide (d18:1/2:0)|GalCer(d18:1/2:0)|N-acetyl Psychosine|β-Gal-C2-Cer

Molecular weight: 503.7

CAS: 35823-61-1

Purity: ≥98%

Formulation: A solid

Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer|Cell Signaling|NF-κB Signaling||Research Area|Cancer|Transcription Factors|NF-κB||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Sphingolipids

Related products

  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 5 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 5 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}

    CAY10512 – 500 mg

    The nuclear factor-κB (NF-κB) regulates the expression of numerous genes involved in immunity and inflammation, cellular stress responses, growth, and apoptosis. Resveratrol, a polyphenolic trans-stilbene, is a known inhibitor of the activation of NF-κB and exhibits activity against a wide variety of cancer cells. CAY10512 is a substituted trans-stilbene analog of resveratrol that is 100-fold more potent as measured by antioxidant activity. The IC50 value for inhibition of TNFα-induced activation of NF-κB by CAY10512 is 0.15 µM compared to 20 µM by resveratrol.{14545}  

     

    Brand:
    Cayman
    SKU:10009536 - 500 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A powerful effector in both the TetR and revTetR transcriptional regulator systems

    Anhydrotetracycline (hydrochloride) – 100 mg

    The tetracycline repressor (TetR) is a transcriptional regulator which normally binds tightly to its palindromic tetO operator DNA, blocking gene expression.{17508} Tet causes the repressor to dissociate from the DNA, allowing transcription to occur. A novel reverse TetR (revTetR) requires tetracycline as a co-repressor to bind tetO and block transcription.{17509,17510} Anhydrotetracycline (hydrochloride) is a powerful effector in both the tetracycline repressor (TetR) and reverse TetR (revTetR) systems, binding the Tet repressor 35-fold more strongly than Tet.{17508,17511} Moreover, anhydrotetracycline poorly binds the 30S ribosomal subunit, compared to Tet,{17512} so it does not act as a general inhibitor of translation and is a poor antibiotic. Perhaps related to this, the concentration of anhydrotetracycline that inhibits eukaryotic cell growth is more than a 1,000-fold above the dose that alters transcription through TetR.{17508}  

     

    Brand:
    Cayman
    SKU:10009542 - 100 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page
  • A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H

    (R)-Roscovitine – 10 mg

    Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}  

     

    Brand:
    Cayman
    SKU:10009569 - 10 mg

    Available on backorder

    Add to quotes
    Add to quotes
    View product page